Lantheus Holdings, Inc. (LNTH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented mixed signals. Financial performance showed declines in profit margins and cash flow, but product developments, especially in the Alzheimer's diagnostics market, are promising. The Q&A highlighted concerns about study designs and pricing pressures but also revealed confidence in strategic expansions. Adjusted guidance and strategic investments indicate cautious optimism, yet the lack of CEO clarity and margin declines temper positive outlooks. Overall, the mixed elements suggest a neutral market reaction.
Key Financial Performance
Revenue for Q4 2025 $406.8 million, an increase of 4% year-over-year. The increase was driven by strong commercial execution and pricing discipline.
Revenue for Full Year 2025 $1.5416 billion, an increase of 0.5% year-over-year. The slight increase was due to price and volume favorability in certain segments.
PYLARIFY Revenue for Q4 2025 $240.2 million, flat sequentially and down 9.7% year-over-year. The decline was attributed to pricing concessions and competitive dynamics.
PYLARIFY Revenue for Full Year 2025 $989.1 million, down 6.5% year-over-year. The decrease was due to pricing concessions and competitive pressures.
Precision Diagnostics Revenue for Q4 2025 $143.2 million, representing a 22% increase year-over-year. This was driven by strong performance in DEFINITY and Neuraceq.
DEFINITY Revenue for Q4 2025 $85.3 million, 1% lower year-over-year. The slight decline was due to prior year competitor supply challenges that had temporarily boosted revenue.
Neuraceq Revenue for Q4 2025 $31 million. This was driven by strong commercial execution and the expanding Alzheimer's disease PET imaging market.
TechneLite and Other SPECT Revenue for Q4 2025 $26.9 million. This segment was part of the legacy business divested on January 1, 2026.
Strategic Partnerships and Other Revenue for Q4 2025 $23.3 million, up 203.3% year-over-year. The increase was due to strong performance of MK-6240 and a $6 million milestone receipt.
Gross Profit Margin for Q4 2025 65.1%, down 289 basis points year-over-year. The decline was due to decreases in PYLARIFY net price and the inclusion of new manufacturing facilities and Neuraceq volumes.
Operating Expenses for Q4 2025 30.9% of net revenue, 179 basis points unfavorable year-over-year. The increase was due to planned investments in R&D and sales and marketing for Neuraceq.
Operating Profit for Q4 2025 $138.9 million, a decrease of 8.5% year-over-year. The decline was due to higher operating expenses and lower gross profit margin.
Adjusted Profit for Q4 2025 $110.7 million, a decrease of 4.1% year-over-year. The decline was due to the same factors affecting operating profit.
Free Cash Flow for Q4 2025 $81.4 million, a decrease of $60 million year-over-year. The decline was primarily due to changes in working capital and increased inventory.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Neuraceq acquisition: Acquired Neuraceq, a beta-amyloid-targeted PET radiodiagnostic, now a cornerstone of the Alzheimer's disease portfolio. Expected growth in 2026 to exceed the market.
OCTEVY acquisition: Acquired OCTEVY, a neuroendocrine PET radiodiagnostic under FDA review, targeting the GEP-NET PET imaging market.
Lantheus 2401: Advanced Lantheus 2401, a Phase III-ready GRPR-targeted radiodiagnostic for prostate cancer, addressing patients who may not express PSMA.
PSMA PET imaging: Maintained leadership in PSMA PET imaging with PYLARIFY, preparing for a new formulation launch in late 2026.
Alzheimer's imaging market: Neuraceq positioned as the second most utilized and fastest-growing beta-amyloid PET imaging agent, addressing a growing demand driven by Alzheimer's disease-modifying therapies.
SPECT business divestiture: Completed divestiture of legacy SPECT business to focus on innovative PET radiodiagnostics.
Manufacturing expansion: Expanded PMF manufacturing network to support Neuraceq and other products.
Focus on radiodiagnostics: Prioritized investment in PET radiodiagnostics, optimizing cost structure and divesting non-core assets.
Pipeline optimization: Exploring alternatives for radiotherapeutic assets to unlock shareholder value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
CEO Transition: The company is undergoing a CEO transition, which could lead to potential disruptions in strategic execution and operational continuity during the interim period.
Regulatory Approvals: Several products are under FDA review, and delays or rejections could impact the company's ability to meet revenue and growth targets for 2026 and beyond.
Competitive Pressures: The PSMA PET imaging market is highly competitive, with potential pricing erosion and renewed competitive dynamics expected in 2026, which could affect PYLARIFY's revenue.
Supply Chain and Manufacturing: The transition to a new PSMA PET formulation and expansion of the PMF manufacturing network for Neuraceq could face logistical challenges, potentially impacting product availability and customer satisfaction.
Economic and Market Conditions: Economic uncertainties and market dynamics, such as pricing concessions and 340B pricing resets, could negatively affect revenue and profitability.
Pipeline and Portfolio Management: The company is pursuing value-maximizing alternatives for its radiotherapeutic assets, which could lead to delays or challenges in unlocking their value.
Integration of Acquisitions: The integration of recent acquisitions, such as Neuraceq and OCTEVY, is critical, and any delays or inefficiencies could hinder the realization of their full value.
Litigation Risks: The company is awaiting a court ruling on Hatch-Waxman litigation related to PNT2003, which could impact its commercialization plans and financial outcomes.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company forecasts worldwide net revenue of $1.4 billion to $1.45 billion for 2026. PYLARIFY net revenue is expected to decline 8% to 10% year-over-year, with increased volume offset by modest price erosion. Neuraceq is projected to grow triple digits inorganically, and DEFINITY is expected to grow low to mid-single digits.
Product Launches and Approvals: The company anticipates multiple FDA approvals in 2026, including a new PSMA PET formulation (PDUFA date: March 6), OCTEVY (PDUFA date: March 29), PNT2003, and MK-6240 (PDUFA date: August 13). Commercial launches for these products are expected to begin in the second half of 2026, with material revenue impact starting in 2027.
Strategic Focus: The company will prioritize investments in radiodiagnostics and optimize its cost structure to align with this focus. It plans to pursue value-maximizing alternatives for its radiotherapeutic assets and does not anticipate significant M&A activity in 2026, focusing instead on integrating recent acquisitions.
Operational Changes: The company will transition its PMF channel partners from PYLARIFY to the new PSMA PET formulation on a rolling geographic basis in Q4 2026. This transition is expected to minimize risk and position the new formulation for sustainable growth starting in 2027.
Market Trends and Growth Drivers: The company expects growth in the Alzheimer's disease PET imaging market, driven by increased adoption of disease-modifying therapies and expanded diagnostic guidelines. Neuraceq is positioned as the second most utilized and fastest-growing beta-amyloid PET imaging agent.
Financial Projections: Gross margin is expected to remain at approximately 65.5%. R&D expenses will increase to 10%-11% of revenue, reflecting investments in late-stage pipeline projects. The effective tax rate is projected to rise slightly to 26%, and fully diluted shares outstanding are expected to average 66 million shares for the year. EPS is forecasted in the range of $5 to $5.25.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company repurchased $100 million or $1.77 million of its own shares during the quarter, leaving $200 million of authorization for buybacks outstanding.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the timing for securing coding and reimbursement rates for the next-gen PSMA PET imaging agent?
A:The HCPCS code and transitional pass-through status are expected to be in place by October 1, following a submission by June 1. The operational rollout is planned for late 2026, specifically in the fourth quarter, with significant revenue expected in 2027.
Q:What are the concerns regarding the POSLUMA versus PYLARIFY head-to-head study?
A:Concerns include lack of randomization, no truth standard, potential credit for false positives in detection rate, and the study not being powered to show statistical significance. Additionally, the study design does not align with current clinical practices.
Q:What were the pricing and unit growth dynamics for PYLARIFY in Q4 '25?
A:PYLARIFY experienced 4% volume growth and mid-teens growth in gross-to-net price change, slightly exceeding expectations. The single greatest volume performance occurred in Q4.
Q:What are the market assumptions for PYLARIFY in 2026?
A:The company expects low single-digit volume growth and incremental price adjustments, with a continuation of disciplined pricing strategy. The guide assumes a sequentially net revenue-neutral outcome for each quarter in 2026.
Q:What is the company's strategy for radiotherapeutic assets and potential tuck-ins?
A:The company is focusing on diagnostic assets while considering value-maximizing alternatives for therapeutic assets. They are open to tuck-ins for diagnostic opportunities if they fit strategically. PNT2003 is excluded from external alternatives as it is close to regulatory approval and fits naturally into the portfolio.
Q:Why is Neuraceq's growth forecasted at triple digits but not higher?
A:Neuraceq's growth is limited by its manufacturing footprint, which is being expanded. The company plans to add 6 more PMFs in 2026 to broaden geographic coverage and deepen penetration in existing accounts.
Q:How does the company view the role of tau in the market?
A:The company believes there is strong scientific evidence linking tau presence and quantification with cognitive performance. Tau imaging is expected to complement disease-modifying therapies for Alzheimer's disease.
Q:What is the status of the CEO search?
A:The CEO search is progressing well, with strong candidates being considered. The company is leveraging its proximity to the active life sciences market in Cambridge.
Q:What are the growth opportunities for Neuraceq compared to competitors?
A:Growth opportunities include broadening geographic footprint, leveraging existing relationships with nuclear medicine customers, and deepening penetration in accounts where PYLARIFY is already used. The focus is not on price competition.
Q:What are the expectations for revenue contributions from the product portfolio?
A:Prostate cancer products, particularly PYLARIFY, will remain the cornerstone of revenue. Other products like Neuraceq and new launches will contribute, but significant revenue from new products is expected in 2027.
Q:What are the product-specific and commercial infrastructure differentiations for OCTEVY and PNT2003?
A:OCTEVY will benefit from transitional pass-through status, which is significant for hospital-based markets. PNT2003 is a natural fit into the portfolio and customer base, with a focus on leveraging existing relationships.
Q:What are the sales and marketing expense expectations for 2026?
A:Sales and marketing expenses are expected to be around 12-12.5% of revenue, with investments focused on preparing for product launches in 2027. The company aims to leverage existing customer relationships to optimize spending.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about the timing of the CEO search, providing general comments about the progress and candidate pool without specifying a timeline.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Amanda
FDA review
GA
GEP NET
Lutathera
MK stage
Neuraceq
PDUFA date
PET formulation
PET radiodiagnostic
SPECT
activity
amyloid PET
asset portfolio
asset radiodiagnostics
base portfolio
base value
baseline
category
commercialization
customer base
decrease period
divestiture
expansion PMF
formulation OCTEVY
imaging market
increase basis
intent
launch timing
market access
marketing
medicine customer
mid term
milestone
place
portfolio product
priority
readiness
stage asset
transition
LNTH Transcript
Cars.com Inc. (CARS) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call reveals mixed signals: positive aspects include operational efficiency, a strategic focus on AI, and a continued stock buyback program, indicating confidence in undervaluation. However, there's a lack of clarity in growth timelines and flat OEM revenue expectations. The strategic plan shows potential with new product launches and market expansion, but immediate financial guidance is weak. The Q&A reflects cautious optimism but highlights uncertainties, especially in growth and revenue. Overall, the sentiment is neutral due to balanced positive and negative factors, lacking strong catalysts for significant stock movement.
Lantheus Holdings, Inc. (LNTH) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presented mixed signals. Financial performance showed declines in profit margins and cash flow, but product developments, especially in the Alzheimer's diagnostics market, are promising. The Q&A highlighted concerns about study designs and pricing pressures but also revealed confidence in strategic expansions. Adjusted guidance and strategic investments indicate cautious optimism, yet the lack of CEO clarity and margin declines temper positive outlooks. Overall, the mixed elements suggest a neutral market reaction.
Lantheus Holdings, Inc. (LNTH) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call reveals several negative indicators: reduced revenue guidance, declining gross profit margins, and increased operating expenses. The Q&A section shows management's reluctance to provide specific guidance for 2026, adding uncertainty. Despite some positives like new product launches and a stock repurchase program, the overall sentiment is negative due to financial declines and management changes. These factors, combined with competitive pressures and lack of clear future direction, suggest a likely negative stock price movement.
Lantheus Holdings, Inc. (LNTH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-9
LNTH Slides
LNTH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
